TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Avenacy Launches Furosemide for Injection in the U.S. Market

Thursday, March 21, 2024

Avenacy, a specialized pharmaceutical company focused on providing essential injectable medications, has announced the introduction of Furosemide for Injection in the United States. This product serves as a therapeutic equivalent generic for Lasix® for Injection (furosemide), approved by the U.S. Food and Drug Administration. Furosemide is prescribed for adults and pediatric patients for the treatment of edema associated with congestive heart failure, liver cirrhosis, renal disease, including the nephrotic syndrome, and situations where a potent diuretic is needed.

Jeff Yordon, Co-Founder and CEO of Avenacy, expressed excitement about the company's progress, stating, "The launch of Furosemide for Injection builds on the two launches announced earlier this week and further demonstrates the speed at which we are progressing the business." With five products launched since their establishment in October, Avenacy aims to continue launching more than 20 products this year.

Avenacy's Furosemide for Injection will be available in packs containing 25 units of 100 mg/10 mL doses. The company emphasizes patient safety and efficient care by providing highly differentiated packaging and labeling to facilitate accurate medication selection. Shipments to wholesale partners will commence next week, supported by Avenacy's global network of development and FDA-approved cGMP-certified contract manufacturing partners.

Furosemide for Injection achieved U.S. sales of approximately $33 million in the twelve months ending in June 2023.

For further information about Avenacy's products or the company's growth plans for 2024, interested parties are encouraged to meet with the Avenacy management team at DCAT Week 2024 in New York City from March 18-21st. Requests for meetings can be directed to

A warning is issued regarding the potent nature of Furosemide, highlighting the need for careful medical supervision to prevent electrolyte depletion. The full prescribing information, including boxed warning, can be found in the provided link.

Furosemide is indicated as adjunctive therapy in acute pulmonary edema, particularly when rapid diuresis is required. In cases where oral administration is impractical or gastrointestinal absorption is compromised, intravenous or intramuscular administration of furosemide is recommended. Parenteral use should be transitioned to oral furosemide as soon as feasible.

Lasix® is a registered trademark of Sanofi S.A.



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit